#BIO22: Coming together at a critical time, Endpoints News looks at the key metrics on biopharma in a turbulent time

Bioregnum Opinion Column by John Carroll

Back at the beginning of the year during JP Morgan, I came up with my usual set of projections for the year ahead and definitely got one thing wrong. The biotech IPO market, I said in January, would remain weak, creating a major funding issue for biotech.

Here’s me in a discussion with Catalent executive chairman John Chiminski:

What you’ve had for several years is a booming biotech field, lots of money pummeling into the business and pushing it up. So when you remove IPOs as an alternative source of money for a lot of companies, it will make deal-making more (attractive).

That was directionally correct, but the IPO market didn’t stay weak. It imploded in an ugly ball of startled generalist fear as Ukraine, inflation and a world of fretting sent the IPO market — which backed…
Click here to view original post